Although the economic recession has clearly affected the U.S. tea market, slowing previously double-digit sales growth in the pricier RTD segment while slightly lifting sales in the more affordable bags/loose tea segment, tea’s appeal as an “affordable luxury” and its compelling image as a healthy product have kept sales in the black when many other CPG categories have seen declines. Moreover, considering the 2005-2009 period overall, sales have done well, and as the economic picture brightens the recession may turn out to have a silver lining in that it has compelled tea marketers to innovate along value-added lines likely to continue to resonate well with consumers in the years ahead.

Market thrusts examined in the report include exotic superfruit flavors; hybrid products designed to compete with other beverage categories including bottled waters, energy drinks and sodas; new RTD spins on green tea that promise to mainstream this tea type once and for all; emerging segments including yerba mate and Kombucha; the upswing in fair trade and other “ethical” appeals; social marketing via nontraditional media like Facebook and Twitter; and a strong tea push in the convenience store channel by marketers and operators alike. At the same time, foodservice players from fine restaurants on down are expanding their tea offerings even as tea rooms and coffee/tea shops surge, suggesting tea may be headed toward much broader levels of distribution and popularity à la Starbucks.

This fully updated report examines the U.S. market for tea across the retail and foodservice spectrum, including ready-to-drink (RTD) tea, leaf (bagged and loose) tea, and instant tea. Following an introductory chapter documenting tea types, packaging trends, “the ethics of tea,” and global market trends, the report segments and quantifies the market by channel and product type, providing historical sales figures and projections through 2014. The report examines market drivers and trends and thoroughly maps out the competitive situation to the marketer and brand share level, profiling brands including Arizona RTD Tea (Ferolito, Vultaggio & Sons), Bigelow Tea (R.C. Bigelow, Inc.), Celestial Seasonings (The Hain Celestial Group, Inc.), Honest Tea (Honest Tea, Inc.), Lipton (Unilever) and Starbucks and Tazo Tea (Starbucks Coffee Co.). Trends in new product introductions are analyzed at length, based on data from Datamonitor’s Product Launch Analytics, as are trends in the c-store and foodservice channels.

An exclusive feature of this report is custom survey data from Packaged Facts’ February 2009 online poll of 2,600 U.S. adults, which was conducted to measure purchasing patterns, attitudes and demographics specific to tea and other functional foods and beverages. Drilling down to the brand level, the analysis also relies on consumer survey data from Experian Simmons’ Spring 2009 National Consumer Study to chart consumer demographic and psychographic trends, Information Resources, Inc. InfoScan Review data tracking product sales in mass-market channels, and wholesale data from leading natural/specialty channel distributor United Natural Foods, Inc. (UNFI) to quantify sales and market shares of natural and specialty products.

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/1716/Tea-and-Ready-to-Drink-RTD-Tea-in-the-U-S-Retail-Foodservice-and-Consumer-Trends.html

Contact us:

Visionshopsters
Ph : 91-22-40583020
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com

The commercial payment card market has undergone a transformation in recent years as the associations and issuers strive to convince companies of the various benefits. Once a fairly simple market comprising travel and entertainment cards and fuel cards, the commercial payment card universe has become more complex with increased segmentation and functionality. But the lines between products have also blurred resulting in card products that combine several cards into one. Purchasing cards have emerged as the champion of commercial payments with the expectation of eventually replacing a substantial portion of paper-based procurement. The fact that commercial cards capture a mere fraction of total commercial payments highlights the potential of the opportunity at hand.

The financial crisis of 2008 that led to the economic meltdown in 2009 posed both a hurdle and an opportunity for the commercial payment card market. On the one hand, products such as small business cards suffered massive declines in purchase volume and skyrocketing charge-off rates. On the other hand, the consolidation of several major issuers and the weeding out of weaker players, combined with a new drive toward corporate cost control and efficiency, may have set the stage for a quick recovery in 2010.

This Packaged Facts report, which has been renamed from corporate credit cards, presents data and analysis on the global and U.S. market for commercial payment cards. The report presents the size and growth of the market by examining key metrics for the 2005-2009 period and providing forecasts through 2014. Included are discussions and analysis of the various commercial payment card types, trends and factors affecting their growth, and a focused analysis of commercial card end user demographics and preferences. In addition, major card brands and issuers are profiled to provide a competitive landscape.

Methodology

Packaged Facts’ study of commercial payment cards is based on extensive secondary research and interviews with industry and regional experts. Secondary sources include data-gathered from relevant trade, business, and government sources, including card industry journals, trade and general press (print and electronic), annual reports and 10(k) filings, company literature, consultancy publications, Packaged Facts reports, websites and white papers.

Packaged Facts’ analysis of consumer behavior and demographics derives from the spring 2009 Experian Simmons Market Research Bureau’s (New York, NY) adult consumer surveys, which are based on approximately 25,000 respondents age 18 or over.

What You’ll Get in this Report

Commercial Payment Cards makes important predictions and recommendations regarding the future of this market, and pinpoints ways current and prospective players can capitalize on current trends and spearhead new ones. No other market research report provides both the comprehensive analysis and extensive data that Commercial Payment Cards offers.

Plus, you’ll benefit from extensive data, presented in easy-to-read and practical charts, tables and graphs.

How You Will Benefit from this Report

If your company is already doing business in the commercial payment card market, or is considering making the leap, you will find this report invaluable, as it provides a comprehensive package of information and insight not offered in any other single source. You will gain a thorough understanding of the current market for commercial payment cards, as well as projected markets and trends through 2014.

This report will help:

• Marketing Managers identify market opportunities and develop targeted promotion plans for commercial payment cards.
• Research and development professionals stay on top of competitor initiatives and explore demand for commercial payment cards.
• Advertising agencies working with clients in the banking and retail industries understand the product buyer to develop messages and images that compel businesses to use commercial payment cards.
• Business development executives understand the dynamics of the market and identify possible partnerships.
• Information and research center librarians provide market researchers, brand and product managers and other colleagues with the vital information they need to do their jobs more effectively.

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/1715/Commercial-Payment-Cards-The-U-S-and-Global-Markets-and-Trends-6th-Edition.html

Contact us:

Visionshopsters
Ph : 91-22-40583020
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com

As the U.S. economy slid deeper into recession during 2009, coffee marketers and foodservice operators moved in the opposite direction, digging out of the trench of 2008 with a variety of strategies designed to capitalize on the fact that even upscale coffee is a relatively thrifty luxury that offers comfort during stressful times. Two success stories were the rebound of Starbucks on the foodservice side and the revitalization of the former P&G retail coffee portfolio by J M. Smucker. Although the era when the coffee market grew effortlessly through premiumization may have ended, such upscale trends as the shifts towards specialty coffee beverages, gourmet beans and ethical consumerism are still clearly in force. What’s more, there’s ample opportunity for companies to capitalize on such trends as the economy recovers—not by ignoring the tougher times or reversing strategy, but by crafting an image that’s both upscale and responsive to consumers’ stronger-than-ever demand for value.

Packaged Facts’ Coffee and Ready-to-Drink Coffee in the U.S.: The Market and Opportunities in Retail and Foodservice, 6th Edition offers a comprehensive look at this $47.5 billion market, examining both the retail and foodservice sides of the business as well as the growing overlap of the two. On the retail side, the report analyzes coffee sold for future brewing—beans and ground, and instant—as well as RTD coffee drinks (à la Frappuccinos), as well as coffee enthusiast’s new brewing method of choice: single-serve (pod) coffee. Positive upscaling trends that slowed during the weak economy will gradually regain the upper hand, the report predicts, resulting in increasing annual percentage sales gains lifting sales by 23% by 2014 to reach $58.3 billion. The report examines sales across the entire retail universe, using Information Resources, Inc. InfoScan Review data and SPINSscan data to extensively chart performance, market composition and marketer/brand performance for the mass-market and natural supermarket channels.

Comprehensive coverage is also devoted to the vast foodservice market for coffee, including the expansion of specialty drinks at such mass-market venues as McDonalds, Dunkin’ Donuts and, most recently, Burger King with its planned 2010 roll-out of Starbucks’ Seattle’s Best. Supplementing the market tracking and forecasting of previous editions, Coffee and Ready-to-Drink Coffee in the U.S.: The Market and Opportunities in Retail and Foodservice, 6th Edition pays special attention to trends in new product development, inclusive of valuable global perspective; details competitive opportunities, including via in-depth company profiles; explores winning marketing methods including Web-based activity; and provides detailed consumer profiling using Experian Simmons data for 2009.

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/2217/Coffee-and-Ready-to-Drink-Coffee-in-the-U-S-The-Market-and-Opportunities-in-Retail-and-Foodservice-6th-Edition.html

Contact us:

Visionshopsters
Ph : 91-22-40583020
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com

From Kalorama Information a unique tool for assessing the diagnostic business today. Working in conjunction with premier diagnostic survey database Emmes Group, Kalorama Information presents the summarized results from a recent survey of a critical mass of diagnostic labs in the U.S, with analysis from Kalorama’s leading diagnostic analyst, Shara Rosen.

Far more than any other market research report, this report provides the most current and accurate picture of what is truly going on in molecular diagnostics in the United States.

Quantitative Data

Analyzed by the best-selling author of The Worldwide Market for In Vitro Diagnostics, now in its sixth edition, this new report includes surveys of molecular diagnostics focusing on these tests:

• Chlamydia and Gonorrhea
• HBV Viral Load
• HCV Viral Load, HCV Genotyping
• HIV Viral Load, HIV Genotyping
• HPV, HPV Genotyping
• Hospital Acquired Infections – MRSA, VRE
• Coagulation Factors – Factor II, Factor V Leiden
• Herpes Simplex Virus (HSV)
• Oncology Tests – BCR/ABL, Bladder Cancer, Her2Neu, MTHFR
• Transplant Medicine – HLA Typing
• Hereditary Disorders – Cystic Fibrosis (CF), Fragile X
• Respiratory Infections – Influenza A/B, Group A Strep, MTB (Tuberculosis), Bordetella pertussis, Adenovirus, Respiratory Virus
• Communicable Diseases – CMV (Cytomegalovirus), EBV (Epstein-Barr Virus), Group B Strep, Enterovirus

What Labs Do Now, What They are Planning in the Future

There has been much analysis in recent years about the inroads that DNA testing has made. This unique resource offers a way to measure that progress, and test assumptions aobut the evolution of DNA testing, critical information to adjust business stratetgies. This report looks at the following topics:

• What type of reagents are labs using (Commercial, ASR, Homebrew)
• Where tests are performed (Central/Core Testing Lab, Chemistry Lab, Cytology Lab, Genetics Lab, Hematology Lab, Microbiology Lab, Molecular Lab, Pathology Lab, Serology/Immunology Lab, Virology Lab)
• What Vendors are Labs Using
• What are there Purchasing Plans
• What Tests Do They Want in the Future
• Do They Outsource and at what Rate?
• Do They plan Vendor Changes?

A Representative Sample of the US Hospital Lab Industry

Emmes Group reached an extensive sample group – interviewing 14% of US hospital labs, 14% of public labs and 8% of US reference lab, where Emmes respondent numbers are compared to the Americian Hospital Directory. Such an undertaking would cost an individual company tens of thousands of dollars. This information is available to purchasers of this report at a fraction of the cost.

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/1631/Who-s-Doing-What-in-Molecular-Diagnostics-Kalorama-Emmes-Survey-of-US-Laboratories.html

Contact us:

Visionshopsters
Ph : 91-22-40583020
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com

Molecular diagnostics represents a revolution postponed, perhaps, but one that is now clearly underway. DNA Testing has emerged fully from research into clinical practice and becoming a dominant platform in clinical medicine.

From Emerging to Emergent Technology

Instrumentation now automates many of the sample preparation and assay steps that were formerly labor intensive. New tests are being launched all the time. At each step of the way, Kalorama Information has reported on its progress, and in this latest market research report we look at the present state of the market, and the advances that have made DNA testing routine.

Many molecular tests are CE Marked and FDA-cleared and many more are in development. The result is that molecular testing is indicated in many areas of health care.

Molecular Testing Compiled and Analyzed and Explained by a Leading Expert

Authored by lead Kalorama diagnostic analyst Shara Rosen, Kalorama Information’s World Market for Molecular Diagnostics is the most comprehensive global market report available on the emergent field of molecular diagnostics.

This report covers key platforms of molecular diagnostics, including the following :

• Polymerase Chain Reaction (PCR)
• Non-PCR Amplification Technologies, including:
  • bDNA
  • TMA
  • SDA
  • LIPA
  • NASBA
  • Invader
  • Others
• In-situ Hybridization
• Sequencing
• Microarrays
• Laser Capture Microdissection (LCM) and Tissue Arrays
• Mass Spectroscopy
• Other Molecular Platforms

This report provides market estimates and analysis for molecular diagnostics in the following categories:

• Infectious Diseases (including HIV, Hepatitis GC/Chlamydia,Organism ID, MRSA, HAI et al, Mycobacteria, TB Respiratory, Others)
• Blood Screening
• Histology
• Oncology
• Prenatal
• Coagulation
• Tissue Typing
• Inherited Diseases
• Pharmacodiagnostics

The various clinical techniques and trends are discussed from the point of view of their present and potential market impact.

Market analysis in this report covers world markets for in vitro diagnostics, with focus on the developed areas of the globe — North America and Western Europe. However public health and infectious disease are a growing global problem and where possible the report covers IVD products related to the globalization of diseases.

As part of its exhaustive coverage of nucleic acid testing, the report includes the following:

• Market Sizes and Forecasts
• Profile and Assessment of Over 140 Key Competitors
• Breakout of Molecular Diagnostic Market by Region (N. America, W. Europe, Asia, ROW)
• Medical and Technological Trends
• Discussion of Globalization of Markets and Diseases
• Information on Reimbursement of New Technologies
• Review of Novel Test Platforms
• Review of New Market Developments, Such as Consumer Genomics and Testing Services
• Discussion of Market Impact of Home Brew Tests
• Discussion of Diagnostic Biomarkers and Genetic Indicators

All market data are based on factory sales to the end user and not retail pricing or reimbursement payments. Data for the molecular test market are presented in U.S. dollar market size for categories of tests, and for specific analytes where possible. The dollar value of a market segment is directly proportional to the number of tests performed, because the cost of the instrumentation is generally buried in the per test price.

The report discusses tests and technologies that are currently available and those that are expected to take their place. Generally, current products and technologies establish the standard of care and its value to payers. Many of the assays and techniques presented in the report are expected to replace the standard of care in 2007/08, but with healthcare systems’ emphasis on cost/benefit analysis for new technologies adoption, the market value and thus penetration capabilities of newer approaches may be limited.

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/1621/The-World-Market-for-Molecular-Diagnostics.html

Contact us:

Visionshopsters
Ph : 91-22-40583020
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com

This Kalorama Information report – Clinical Nutrition – focuses on three primary segments of essential medical nutrition:

• Infant Nutrition: (Milk-based, Soy-based, Special Needs such as Chronic Reflux or Gastrointestinal Discomfort)
• Enteral Nutrition (Standard and Fiber-containing Elemental and Semi-elemental, Specialized for Chronically Ill Patients)
• Parenteral Nutrition

For each category, the report provides revenue data and forecasts for the most important segmentations. The report includes incidence of conditions which often require enteral or parenteral feeding, birth rates, over 65 population, and overall global population. Information is presented as a worldwide overview, with special emphasis on the U.S., Europe, and other key markets. The market segments provide an overview, description of products on the market, new developments, market estimates and forecasts, and competitive analysis of leading providers. The report also includes current issues and trends affecting the industry.

Coverage of Issues and Trends in Clinical Nutrition

There are several issues and trends that are impacting the clinical nutrition market, including:

• Wound Care Applications
• Reimbursement of Nutrition Products
• Food Programs
• Nutrition and Education
• DHA and ANA Additives
• Counterfeit Infant Formulas
• Recalled Infant Formulas
• Acquisition, Mergers and Alliances
• Technology Applications

A Growing Market with Thriving Competition

Competition in the clinical nutrition market is dominated by a handful of companies, ranging from global nutritional manufacturers to leading pharmaceutical companies. The majority of competitive participation is in developed regions such as the United States, Western Europe, and Japan. However, many companies are expanding into less developed regions, intensifying competition in less tapped markets. China, for example, is among the expanding competitive regions as companies continue to break into the growing demand for clinical nutrition in new world markets. Companies highlighted in this study include:

• Abbott Laboratories
• Baxter International
• B. Braun
• Danone
• Fresenius Kabi
• Mead Johnson
• Nestle
• PBM Products
• Wyeth

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information.

For the purpose of this study, Kalorama Information conducted interviews with more than 80 key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with nutrition company representatives included marketing directors, division managers, and product representatives. All market data pertains to the world market at the manufacturers’ level.

The base year for data was 2008. Historical data was provided for the years 2006 and 2007, with forecast data provided for 2009 through 2013. Compound annual growth rates (CAGRs) are provided for the 2006-2008, 2008-2013 and 2006-2013 periods for each industry segment covered. Competitive analysis is provided for the year 2008. The forecasted market analysis for 2009-2013 was based on demographic trends, new developments, and global expansion.

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/1626/Clinical-Nutrition-Products-World-Markets-3rd-Edition.html

Contact us:

Visionshopsters
Ph : 91-22-40583020
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com

The global market for human vaccines has experienced strong growth through 2008 and this is expected to continue through the forecast period. Growth will be fueled by new product introductions and rising usage in all regions.

This report, Vaccines 2009: Key Players, and Critical Trends in a Fast-Changing Industry), examines the market for vaccines used in humans to previous various types of disease. Sales estimates for each market segment represent global revenues and are expressed in current dollars. Estimates are provided for the historic 2008 period and forecasts are provided through 2013.

Since the last edition of this report:

• Vaccine makers are now advertising directly to the public with growing DTC budgets. The report identifies the possible market impact of this new trend.
• The economy has impacted vaccine sales with more people unable to make required out of pocket payments for vaccination.
• New categories of vaccines, such as allergy vaccines, are becoming more prominent, and have been included in our forecasts.
• Several major new products, including Wyeth’s Prevnar 13, are on the horizon. The market impact of new products is discussed.
• Two major mergers – Pfizer/Wyeth and Merck/Schering-Plough, will impact the industry and this is considered in our market analysis.

Few areas of pharmaceuticals have seen the fast-moving developments in the marketplace that the vaccine market has in 2008. Since Kalorama Information last updated Kalorama Information’s The World Market for Vaccines last year, new products and better than expected profits have transformed the vaccine marketplace. Continued sales of influenza vaccines and cervical cancer vaccines have provided a foundation for growth in the adult market. The competitive dynamics have changed with mergers, and many new products are on the way.

Kalorama Information’s exhaustive research and analysis built from interviews with key decision makers in the market includes the following:

• Review of Products in the Market
• Current World Market Size for Pediatric and Adult Vaccines
• Segmented Revenues and Forecasts to 2013 by Category
• Over 45 Charts and Tables To Make Information Accessible
• Discussion of The Current Economy and Vaccines, Immunization Refusal, Swine/Avian Flu and Other Pandemics, Delivery Sys and other Trends in the Vaccine Market
• Important Vaccines and Immunization Schedules and Statistics
• Profiles of 15 Key Vaccine Companies
• Thorough Review of the Vaccine Pipeline and Possible Impact of New Products

Who are the main players in the vaccine market? What opportunities are available for pharmaceutical companies or investors from this market? What are the potential challenges vaccine competitors must deal with? What will be the impact of the first successful cancer product? What is the significance of at least one major acquisition to affect this industry? These questions and more are tackled in this report.

Current revenues and revenue forecasts to 2013 are included for the following pediatric vaccine categories:

• DTaP & DTP Vaccines
• Hep Vaccines
• HiB Vaccines
• MMR Vaccines
• Combination Vaccines
• Pneumococcal Vaccines
• Polio Vaccines
• Varicella Vaccines
• Other Pediatric Vaccines

As well as Revenues and Forecasts to 2012 for the following adult vaccine categories:

• Influenza Vaccines
• Hepatitis Vaccines
• Pneumococcal Vaccines
• Travel, DT and other Adult Vaccines
• Cervical Cancer

This is a rapidly changing marketplace and knowledge of the R&D pipeline is essential to truly understand what is happening in vaccines. Vaccines in development are discussed in this report, including vaccines for the following conditions:

• Enterotoxigenic Escherichia coli
• Parainfluenza Virus Type 3
• Pneumococcal Vaccines
• Respiratory Syncytial Virus<
• Cancers
• Cholera
• HIV/AIDS
• Helicobacter Pylori
• Malaria
• Rabies
• Tuberculosis
• West Nile Virus

This Kalorama Information report was created with a primary research effort. Historical information for this report was gathered from a wide variety of published sources including company reports and filings, government documents, legal filings, trade journals, newspapers and business press, analysts’ reports and other sources. Interviews with company representatives and other experts were conducted to capture the perspectives from industry participants’ point of view and assess trends, and form the basis of the forecasting and competitive analysis.

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/1645/Vaccines-2009-World-Market-Analysis-Key-Players-and-Critical-Trends-in-a-Fast-Changing-Industry.html

Contact us:

Visionshopsters
Ph : 91-22-40583020
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com

Since the last edition of Kalorama Information’s DNA Sequencing Equipment and Services report, the market has been changing in unpredictable ways as second-generation sequencers are being incrementally introduced and upgraded. On the surface, the situation has become somewhat linear and predictable, but as Kalorama Information biotech analyst Justin Saeks explains, it is actually a unique and relatively volatile situation that is not seen often with life science tools markets. Third-generation systems have the potential to completely change the market, or to simply join the pack.

Revenue growth has been unusually high, and all of the trends seem to indicate that growth will continue in the near term. It is likely that completely new technologies will be introduced at least every year or two, while second-generation sequencer improvements also continue. In Kalorama Information biotech analyst Justin Saek’s 2nd edition of DNA Sequencing Equipment and Services Markets, these changes are detailed and put in context, along with the following:

• DNA Sequencer Revenues by Industry and by Leading Systems
• Forecast of Sequencer Revenues to 2014
• Review of Important Sequencers and Comparison of Features and Drawbacks.
• Profiles of Major Companies in the Marketplace
• Affymetrix and Illumina Settlement and other Significant Litigation in the Industry
• Major Industry Deals since 2008, Review of Deals 05-07, and Analyst Commentary
• Over 70 Figures and Tables making market information accessible
• Review of Major Deals and Litigation affecting the marketplace.
• Review of Technologies Under Development
• Discussion of Funding Sources and Recent Grant Awardees
• Strategic Recommendations for Companies Operating in the DNA Sequencing Market

Kalorama Information’s DNA Sequencing Equipment and Service Markets represents research culled from a variety of secondary sources. But the true insights originated from interviews with market experts; these interviews were used to confirm numbers and test forecast assumptions.

Companies profiled in the report include:

• 454 Life Sciences / Roche
• Applied Biosystems / Life Technologies
• Beckman Coulter (Fullerton, CA)
• GE Healthcare Life Sciences
• Helicos Biosciences
• Illumina / Solexa
• LI-COR Biosciences (Lincoln, NE)

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/1650/DNA-Sequencing-Equipment-and-Services-Markets-2nd-Edition.html

Contact us:

Visionshopsters
Ph : 91-22-40583020
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com

As Kalorama Information’s lead diagnostic analyst finds, the point of care concept is at a crossroads: the technologies needed to make rapid testing a reality have arrived. But is healthcare ready?

Kalorama believes that the drive for wellness and the attention surrounding healthcare reform will focus attention on rapid diagnostics. However, according to Shara Rosen, RT, M.B.A., there are many challenges which must be overcome for point of care solutions to be fully utilized, and those companies willing to pivot strategies and best adjust to tomorrow’s healthcare marketplace may be rewarded.

This report, Point of Care Diagnostics 2010: Rapid Testing at a Crossroads represents the most current analysis of the role POC Diagnostics in today’s in vitro industry. Other reports have looked at products, companies and revenue numbers, as this report does. But in her analysis Shara Rosen takes a bold look into the markets, technologies, and trends in decentralized testing with a special focus on the economics of rapid test use in critical care and emergency medicine. The report includes:

• Markets for POC Diagnostics (Diabetes, Cardiac markers, Clinical Chemistry/Critical Care, Hematology, Coagulation, Drugs of Abuse/Therapeutic Drug Monitoring, Infectious Diseases, Pharmacodiagnostics, Sepsis, Oncology, Women’s health / Pregnancy/Fertility)
• By Venue Revenue Estimates for Hospital POC, Physician POC and Other Venue
• Review of Products in the Market
• Forecasts to 2013
• Markets and Forecasts for Self-Testing (OTC)
• The role of EMR in the Point of Care Market
• Possible Effects of Healthcare Reform
• POLs, Home Monitoring, Alternate Samples and Other Trends
• Successful Strategies of POC Companies
• Profiles of Over 100 Companies Competing in this Market

There are many factors in the growth of POC testing- increasing numbers of diagnosed diabetics, people with cardiovascular disease, and other chronic conditions. It is also expected to play a role in a trend in health care to evaluate provider organizations for quality in care delivery. While this quality imperative is most apparent in pay-for-performance systems, it also provides a framework by which public funds can be used more rationally. This is an especially relevant technology given the U.S. healthcare reform efforts.

All countries are feeling the brunt of aging populations and an increased burden of chronic disease management. Employers and insurance companies are interested in improving the health of customers, and there are some innovative tactics developing in this area. The report is conservative in its predictions and offers a calculated look into the future, based on events currently taking place.

The report offers a quantitative assessment of specific markets in US dollars for 2008 and forecasted out to 2013. These data are provided in order to set the status quo of tests and technologies. However the report concentrates on how these will impact the economics of healthcare over the near term and longer when possible.

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/1660/Point-of-Care-Diagnostics-2010-and-Beyond-Rapid-Testing-at-a-Crossroads.html

Contact us:

Visionshopsters
Ph : 91-22-40583020
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com

The global market for human vaccines has experienced strong growth in the past few years, and R&D departments at many pharmaceutical companies are working on new prophylactics, some of which may see near-term marketing. What illnesses may see a vaccine option in the coming years? Which vaccines will have the most successful business model? Who are the major companies in this market, and possible new entrants? What can current vaccine success stories tell us about the future of the vaccine market? This Kalorama Information report What’s Next in Vaccines? examines and estimates the market for vaccines that have yet to be launched, including the following target areas:

• Addiction
• Allergy
• Alzheimer’s Disease
• Anthrax
• Asthma
• Campylobacter Infection
• Chlamydia
• Croup
• Dengue Fever
• Diabetes
• Ebola
• Epstein-Barr Virus
• Enterotoxigenic Escherichia coli
• Helicobacter Pylori
• Hepatitis
• Herpesvirus
• Hookworm
• Hypertension
• HIV/AIDS
• Leishmaniasis
• Malaria
• MRSA Infection
• Multiple Sclerosis
• Obesity
• Parainfluenza Virus Type 3
• Parkinson’s Disease
• Plague
• Respiratory Syncytial Virus
• Ross River Virus
• Shigellosis
• Smoking
• Stroke
• Tuberculosis
• West Nile Virus

Some of these vaccines may see success; some could be the blockbusters of the future. For marketers and industry watchers a knowledge of all of the potential vaccines will be important to understand how pharma is seeking to renew bottom line with aggressive prophylactic strategies, and who the winners and losers in the near future may be. Alison Sahoo has looked at the vaccine market three times in as many years for Kalorama Information, and in this report applies a knowledge of what companies have done in the past to potential efforts.

There are a number of trends that will impact the industry that market watchers will want to know about, and Kalorama Information has covered these trends; including: New Vaccine Technologies, DNA Vaccination, Innovative Delivery Systems, Edible Vaccines, Vaccine Patches, Funding Shortfalls. The report also discusses vaccine manufacturing methods and the approval process. In addition, the report focuses on the emerging vaccine activities of the following companies

• Acambis plc
• ACE BioSciences
• AFFiRiS
• ALK-Abello A/S
• Allergy Therapeutics
• Bavarian Nordic A/S
• Baxter Healthcare
• Celldex Therapeutics
• Crucell
• Cytos Biotechnology
• GlaxoSmithKline
• Hawaii Biotech
• Intercell
• Medimmune
• Merck & Co. Inc
• Mymetics
• Nabi Biopharmaceuticals
• Novartis
• Opexa Therapeutics
• Paladin Labs
• Sanofi Pasteur

This report provides forecasted revenues for products in development out to 2020. The report does not does not cover indication expansions of existing vaccine products, nor does it cover vaccines for which products currently exist and are widely available, but may need improvement. Development of vaccines that incorporate new production methods (such as the migration of chicken eggs to mammal, yeast or other cells) is also excluded. Cancer vaccines are excluded as Kalorama has an entire report on this topic.

Sales estimates for each market segment represent global revenues and are expressed in current dollars. Information for this report was gathered from a wide variety of published sources including company reports and filings, government documents, legal filings, trade journals, newspapers and business press, analysts’ reports and other sources.

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/1594/What-s-Next-in-Vaccines-HIV-Malaria-Rabies-MRSA-and-30-Other-Vaccine-Targets-in-the-2010-2020-Pipeline.html

Contact us:

Visionshopsters
Ph : 91-22-40583020
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com